Naphtho[2,3-B]furan-4,9-diol | 645413-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: Naphtho[2,3-B]furan-4,9-diol
• 英文别名: benzo[f][1]benzofuran-4,9-diol
• CAS: 645413-89-4
• 化学式: C₁₂H₈O₃
• 分子量: 200.19
• InChiKey: ZLNMFKYGGBXDJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE SUSPENSIONS AQUEUSES DE NANOPARTICULES DE DÉRIVÉS D'ESTERS D'ACIDE ALIPHATIQUE DE 4,9-DIHYDROXY-NAPHTO[2,3-B]FURANE
  申请人：ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD

  公开号：WO2013120229A1

  公开（公告）日：2013-08-22

  Disclosed is a method for preparing aqueous nanoparticle suspensions of derivatives of 4,9-dihydroxy-naphtho[2,3-b]furan aliphatic acid esters. The compositions and the uses of the aqueous nanoparticle suspensions prepared according to the method as described herein are also disclosed.

  公开了一种制备4,9-二羟基萘并[2,3-b]呋喃脂肪酸盐衍生物的水性纳米粒子悬浮液的方法。还公开了根据本方法制备的水性纳米粒子悬浮液的组成及其用途。
• 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20160030384A1

  公开（公告）日：2016-02-04

  The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.

  这项发明提供了萘呋喃化合物，萘呋喃化合物的多晶形态，颗粒形式的萘呋喃化合物，含有一种或多种萘呋喃化合物的纯化组合物，含有一种或多种颗粒形式的萘呋喃化合物的纯化组合物，以及
• [EN] NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES<br/>[FR] NOUVEAUX ESTERS DE 4,9-DIHYDROXY-NAPHTO[2,3-B]FURANNES POUR TRAITEMENT THÉRAPEUTIQUE DE MALADIES
  申请人：ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD

  公开号：WO2012119265A1

  公开（公告）日：2012-09-13

  The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9- dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.

  本发明公开了4,9-二羟基萘并[2,3-b]呋喃的酯类及其制造和使用方法。本发明还公开了将这些酯转化为体内治疗活性4,9-二羟基萘并[2,3-b]呋喃的方法。本发明进一步公开了包含4,9-二羟基萘并[2,3-b]呋喃的酯类的药物组合物，用于治疗包括增殖性疾病在内的各种疾病。
• NOVEL ESTERS OF 4, 9-DIHYDROXY-NAPHTHO [2, 3-b] FURANS FOR DISEASE THERAPIES
  申请人：Jiang Zhiwei

  公开号：US20130345176A1

  公开（公告）日：2013-12-26

  The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.

  本发明公开了4,9-二羟基萘并[2,3-b]呋喃的酯类及其制造和使用方法。本发明还公开了将这些酯转化为体内治疗活性4,9-二羟基萘并[2,3-b]呋喃的方法。本发明进一步公开了包含4,9-二羟基萘并[2,3-b]呋喃的酯类的药物组合物，用于治疗包括增殖性疾病在内的各种疾病。
• [EN] PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE<br/>[FR] PROMÉDICAMENTS DE 4,9-DIHYDROXY-NAPHTO[2,3-B]FURANES PERMETTANT DE CONTOURNER LA POLYPHARMACORÉSISTANCE AUX ANTICANCÉREUX
  申请人：ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD

  公开号：WO2013166618A1

  公开（公告）日：2013-11-14

  The present invention discloses use of prodrug of 4,9-dihydroxy-naphtho[2,3-b]furan derivative for circumventing cancer multidrug resistance. The present invention also discloses use of prodrug of 4,9-dihydroxy-naphtho[2,3-b]furan derivative for the treatment of various types of cancers exhibiting multidrug resistance phenomenon. The present invention further discloses use of the pharmaceutically acceptable composition comprising prodrug of 4,9- dihydroxy-naphtho[2,3-b]furan derivative and method of using said composition in the treatment of various types of cancers exhibiting multidrug resistance phenomenon.

  本发明揭示了使用4,9-二羟基萘并呋[2,3-b]呋喃衍生物的前药以规避癌症多药耐药性。本发明还揭示了使用4,9-二羟基萘并呋[2,3-b]呋喃衍生物的前药用于治疗展现多药耐药现象的各种类型的癌症。本发明进一步揭示了使用包括4,9-二羟基萘并呋[2,3-b]呋喃衍生物的前药的药学可接受组合物，并且揭示了在治疗展现多药耐药现象的各种类型的癌症中使用该组合物的方法。